CARMEN-LC04
Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)
- NCT04394624 ↗
- Terminated
- Sanofi
- Focused
We haven't built an HCP commentary report on CARMEN-LC04 (tusamitamab ravtansine plus ramucirumab; tusamitamab ravtansine plus ramucirumab plus pembrolizumab in previously treated CEACAM5-positive metastatic non-squamous NSCLC) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CARMEN-LC04 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Tusamitamab Ravtansine (SAR408701) Used in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Metastatic, Non-squamous, Non Small-cell Lung Cancer (NSQ NSCLC) Patients With CEACAM5-positive Tumors, Previously Treated With Platinum-based Chemotherapy and an Immune Checkpoint Inhibitor
- Phase
- Phase 2
- Status
- Terminated
- Conditions
- Non-small Cell Lung Cancer Metastatic
- Interventions
- SAR408701; ramucirumab; pembrolizumab
- Arms
- Ramucirumab + SAR408701 · Experimental
- Ramucirumab + pembrolizumab +SAR408701 · Experimental
- Enrollment
- 31
- Primary outcomes
- Doublet Cohort - Part 1: Number of Participants With Study Drug-Related Dose-Limiting Toxicity (DLT)
- Doublet Cohort - Part 2: Objective Response Rate (ORR)
- Triplet Cohort: Number of Participants With Study Drug-Related Dose-Limiting Toxicity
- Sponsor
- Sanofi
- Start
- Aug 31, 2020
- Primary completion
- Mar 6, 2023
- Results posted
- Yes
- Registry record
- NCT04394624 · updated Jun 6, 2025